Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0925 • ACR Convergence 2025
Pathogenic role of SPP1+ macrophages in Rheumatoid Arthritis
Megan M. Hanlon¹, Catherine Manning¹, Kevin Wei¹, Ursula Fearon² and Ellen M. Gravallese³, ¹Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ²Trinity College Dublin, Dublin, Dublin, Ireland, ³Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Synovial tissue macrophages (STMs) represent a mixed population of cells contributing to the pathogenesis of rheumatoid arthritis (RA). We identified an enrichment of Secreted…
Abstract Number: 0834 • ACR Convergence 2025
Heterogeneity in the Association of Genetic Risk for Rheumatoid Arthritis and Resultant Rheumatoid Arthritis Phenotypes
Thomas Riley¹, Austin Wheeler², Bryant England², Grant Cannon³, Brian Sauer⁴, Gary Kunkel⁵, Katherine Wysham⁶, Beth Wallace⁷, Paul Monach⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Geoffrey Thiele², Rui Xiao¹, Scott Damrauer¹⁴, Michael Levin¹⁴, Michael George¹, Ted Mikuls² and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁷Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁸VA Boston Healthcare System, Boston, MA, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: The impact of genetic risk factors on rheumatoid arthritis (RA) phenotype is incompletely understood. Comparing individual genetic variants associated with RA susceptibility to a…
Abstract Number: 0775 • ACR Convergence 2025
Increased Circulating Microbial Small RNA tDR-1 is Associated with Decreased Progression to Future Clinical Rheumatoid Arthritis In High Risk Individuals and Reduces In Vitro Type 1 Interferon Response Gene Expression
Anastasiia Phothisane¹, Tulsi Joishy², Carolina Ramirez-Becerra¹, Zuofei Wang², Qiong Wu³, Jennifer Seifert⁴, Marie Feser⁵, Jill Norris⁶, Kristen Demoruelle⁷, LauraKay Moss⁵, Kevin Deane⁸, V. Michael Holers⁹ and Michelle Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, ³University of Virginia, Charlottesville, VA, ⁴University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Colorado School of Public Health, Denver, CO, ⁷University of Colorado Anschutz Medical Campus, Golden, CO, ⁸University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁹University of Colorado Anschutz Medical Campus, Aurora
Background/Purpose: Microbial small RNAs (sRNAs) can regulate human genes, often with anti-inflammatory effects. We previously showed that an increased plasma concentration of a tRNA-derived RNA…
Abstract Number: 0490 • ACR Convergence 2025
Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted – DMARD in RA: A Systematic Review and Network Meta-analysis
Li Liu¹, Xue-Mei Zhang¹, Zhi-Chun Gu¹ and Jia Li², ¹Ren Ji Hospital, Shanghai Jiao Tong University School Of Medicine, Pu Dong Xin Qu, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: This study aimed to evaluate the infection risks in patients with rheumatoid arthritis (RA) treated with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs),…
Abstract Number: 0474 • ACR Convergence 2025
Real-World Experience of Janus Kinase Inhibitors; Retention and Factors Associated with Discontinuation
Joseph Nathan¹, Bayram Farisogullari², Nicholas Jones³, Mohammad Ayoub³, James Brown³, Sarah Levy³, James Brader⁴, Ayse Ersoy⁴, Blossom Israni⁴, Mark Lloyd⁴, Afzal Latheef⁵, Diane Hill⁵, Amybel Taylor⁶, Darshani Arachchige⁶, Hlaing Chitsu⁶, Helen Linklater⁶, Kunal Lather⁷, Luke Gompels⁷, Eman Elfar⁸, Ritu Malaiya⁸, Pedro Machado⁹ and Patrick Kiely¹⁰, ¹St George's Hospital, London, United Kingdom, ²University College London, London, ³Croydon Health Services NHS Trust, Croydon, England, United Kingdom, ⁴Frimley Health NHS Foundation Trust, Frimley, England, United Kingdom, ⁵St George's University Hospitals NHS Foundation Trust, London, England, United Kingdom, ⁶Surrey and Sussex Healthcare NHS Trust, Redhill, England, United Kingdom, ⁷Somerset NHS Foundation Trust, Taunton, England, United Kingdom, ⁸Epsom and St Helier University Hospitals NHS Trust, Carshalton, England, United Kingdom, ⁹Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ¹⁰St George's University Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: The use of Janus Kinase inhibitors (JAKi) to treat RA and PsA in a real-world setting has not been well described. Our aim was…
Abstract Number: 0458 • ACR Convergence 2025
TyG-BMI Index as a Serological Biomarker for Carotid Plaque and Cardiac Function Changes in Rheumatoid Arthritis
Rebeca L. Polina-Lugo¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Esteban C. Garza-Gonzalez⁴, Jesus Alberto Cardenas-de la Garza⁵, Iris J. Colunga-Pedraza³, Jose R Azpiri-Lopez⁶, Dionicio A. Galarza-Delgado³, Victor M Fraga-Enriquez⁷ and Diego Azamat Salcedo Almanza⁸, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁶Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁷Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁸Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: The Triglyceride-Glucose-BMI index (TyG-BMI) is a reliable method for detecting insulin resistance (IR), with effectiveness comparable to the gold standard. Elevated TyG-BMI levels have…
Abstract Number: 0440 • ACR Convergence 2025
The Painful Truth: Non-Articular Pain’s Impact on Rheumatoid Arthritis Assessment after Initiating a new DMARD for Active Disease
Charis Meng¹, Jing Song², Lutfiyya muhammad³, Caci Julia⁴, Tuhina Neogi⁵, Marcy Bolster⁶, Wendy Marder⁷, Clifton Bingham⁸ and Yvonne Lee⁹, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University Feinberg School of Medicine, Worthington, MN, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Hospital for Special Surgery, New York, ⁵Boston University School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Concord, MA, ⁷University of Michigan, Ann Arbor, MI, ⁸Johns Hopkins University, Baltimore, MD, ⁹Northwestern University, Chicago, IL
Background/Purpose: RA-related pain is typically thought of as pain in the joints. However, non-articular pain (NAP) is also common, persisting in 1/3 of patients with…
Abstract Number: 0359 • ACR Convergence 2025
“VA is a slow-moving ship, but you can steer it”: Clinician Views on Navigating Shared Decision-Making and Anticipated Use of an RA Decision Aid
Alicia Hamblin¹, Dylan Waller², Anaïs Tuepker², Catherine Nasrallah³, Alexandra Bennett², Brooke Jespersen², Joshua Baker⁴, Madhavi Valiveti⁵, gabriela Schmajuk⁶ and Jennifer Barton², ¹UCSF, San Francisco, CA, ²Center to Improve Veteran Involvement in Care (CIVIC) and VA Portland Health Care System, Portland, OR, ³University of California San Francisco (UCSF), San Francisco, CA, ⁴Corporal Michael J. Crescenz VA Medical Center (CMCVAMC) and University of Pennsylvania, Philadelphia, PA, ⁵VAMC Wilmington, Wilmington, DE, ⁶University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Shared decision-making (SDM) is the first overarching principle of the treat-to-target guidelines for rheumatoid arthritis (RA). The quality of SDM varies widely, and its…
Abstract Number: 0191 • ACR Convergence 2025
Advanced therapy use in RA patients with moderate disease activity in a large NHS Foundation Trust in South London, UK
Aoibhinn Kelly¹, Maddalena Rupnik², Nasra Ahmed¹, Mrinalini Dey³ and Elena Nikiphorou⁴, ¹King's College Hospital NHS Foundation Trust, London, United Kingdom, ²Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁴King's College London, London, United Kingdom
Background/Purpose: Moderate disease in rheumatoid arthritis (RA) is defined as a 28-joint disease activity score (DAS28) of 3.2-5.1(MDAS). As per the National Institute for Health…
Abstract Number: 0096 • ACR Convergence 2025
GLUT1-Dependent Targeting and Enhanced Selectivity of a Glucose-Methotrexate Conjugate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Sebastian Makuch¹, Jacek Polański¹ and Wojciech Tański², ¹Wrocław Medical University, Wrocław, Poland, ²Wrocław University of Science and Technology, Wrocław, Poland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease where fibroblast-like synoviocytes (FLS) play a central role in joint inflammation and destruction. Methotrexate (MTX), a…
Abstract Number: 0076 • ACR Convergence 2025
Antibodies to malondialdehyde-acetaldehyde are associated with circulating inflammatory mediators during the preclinical stages of rheumatoid arthritis
Emma Weis¹, Harlan Sayles¹, Geoffrey Thiele¹, Samir Rachid Zaim², Tony Merriman³, Bryant England¹, Xiaojun Li², LauraKay Moss⁴, Jess Edison⁵, Marie Feser⁴, V. Michael Holers⁶, Kevin Deane⁷, Ted Mikuls¹ and Austin Wheeler¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Allen Institute for Immunology, Seattle, WA, ³University of Alabama at Birmingham, Homewood, AL, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD, ⁶University of Colorado, Denver, CO, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO
Background/Purpose: Circulating concentrations of anti-malondialdehyde-acetaldehyde (MAA) antibodies distinguish patients with RA and are detectable years prior to arthritis onset. Recent data demonstrate that anti-MAA antibodies…
Abstract Number: 0055 • ACR Convergence 2025
TCR Signaling Thresholds Govern Anergy and Tolerance in ZAP70 Hypomorphic Models of Autoimmune Arthritis
Yuka Nakao, Astha Patel, Letitia Yang, Steven yu, Arthur Weiss and Judith Ashouri, University of California, San Francisco, San Francisco, CA
Background/Purpose: T cell receptor (TCR) signaling strength is a key determinant of immune tolerance and autoimmunity, yet the threshold needed to prevent pathogenic self-reactivity remains…
Abstract Number: 2682 • ACR Convergence 2025
Methotrexate use and higher age impair humoral response against the recombinant herpes zoster vaccine (RZV) in Rheumatoid Arthritis: a prospective, randomized, placebo-controlled trial
Ana C Medeiros-Ribeiro¹, Lucas Farias², Nadia Emi Aikawa³, Sandra G Pasoto¹, Leonard V Kupa², Carla Saad¹, Andrea Shimabuco², Karina Bonfiglioli⁴, Diogo Domiciano⁴, Andre Franco⁴, Clovis Artur Silva⁵ and Eloisa Bonfa⁶, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ⁵University of São Paulo, São Paulo, São Paulo, Brazil, ⁶Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil
Background/Purpose: The recombinant vaccine against herpes zoster (HZ) (RZV) is recommended by ACR and EULAR for immunocompromised individuals. Short-term observational data from RA cohorts aged…
Abstract Number: 2607 • ACR Convergence 2025
ERS-RA as a Tool for Cardiovascular Risk Prediction in Established Rheumatoid Arthritis: An External Validation
Misti Paudel¹, Katherine Liao², Jon Giles³, Joan Bathon⁴, Hongshu Guan⁵, Brendan Everett⁶, Leah Santacroce⁷, Nancy Shadick⁸, Michael Weinblatt⁹, Pamela Rist⁶ and Daniel Solomon¹⁰, ¹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA, ³Cedars Sinai Medical Center, Los Angeles, CA, ⁴Columbia University, NEW YORK, NY, ⁵Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham & Women's Hospital, Boston, MA, ⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The Expanded Risk Model for Rheumatoid Arthritis (ERS-RA) incorporates traditional CV risk factors and RA-related measures of disease activity and has demonstrated better performance…
Abstract Number: 2283 • ACR Convergence 2025
Arrhythmia Risk in Diabetic Rheumatoid Arthritis Patients: Comparative Analysis of IL-6 Inhibitors versus TNF-α Inhibitors
Sila Mateo Faxas¹, Godbless Ajenaghughrure², Gurjot Singh³, Kim Nguyen³, Nirys Mateo Faxas⁴, Nicole Tejeda⁵ and Kimberly Ramirez Bonetti⁶, ¹Good Samaritan Hospital, Cincinnati, OH, ²Trihealth Good Samaritan Hospital, Cincinnati, OH, ³Trihealth Good Samaritan Hospital, Cincinnati, ⁴Independent Author, Santo Domingo, Dominican Republic, ⁵Independent Author, Cincinnati, ⁶Independent Author, cincinnati, OH
Background/Purpose: Background: Both rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) are independently associated with increased cardiovascular risk, including cardiac arrhythmias. The impact of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].